Jason Kim, MD
Urogynecology and Reconstructive Pelvic Surgery · Stony Brook, NYNPI 1275707846
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $244,257 of the $346,006 with a category attached, or 70.6%. Valencia Technologies Corporation accounts for 77.6% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $134,975, more than ten times the $526 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $717.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$269K
- AbbVie$52K
- Medtronic$9K
- Boston Scientific$7K
- Caldera Medical, Inc$5K
- Axonics, Inc.$2K
- plus $2K from 15 others
Across 41 payments — averaging $4772.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$178K
- Axonics, Inc.$17K
What the payments were for
- Consulting fees$244,25771%
- Speaking & faculty fees$45,22513%
- Travel & lodging$39,10111%
- Food & beverage$17,2165%
- Education$1220%
- Gifts$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 98 | $268,528 |
| AbbVie(2 entities) | 113 | $52,054 |
| Medtronic(2 entities) | 133 | $9,160 |
| Boston Scientific | 23 | $6,992 |
| Caldera Medical, Inc | 14 | $5,424 |
| Axonics, Inc. | 36 | $1,690 |
| 180 Medical, Inc. | 19 | $394 |
| Coloplast | 6 | $360 |
| Astellas Pharma US Inc | 16 | $355 |
| Bluewind Medical | 4 | $228 |
| Sumitomo Pharma America, Inc. | 7 | $158 |
| Avation Medical, Inc. | 2 | $127 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $124 |
| Photocure Inc | 1 | $120 |
| Astellas Pharma Global Development | 1 | $100 |
| Urovant Sciences Inc | 3 | $68 |
| Teleflex LLC | 1 | $47 |
| Bayer | 1 | $24 |
| ABC Home Medical Supply, Inc. | 1 | $23 |
| Olympus America Inc. | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$267,271
- BOTOX$49,852
- Desara$5,060
- INTERSTIM$4,016
- Bulkamid$883
- Axonics$742
- ALTAVIVA$429
- Axonics r-SNM System$402
- Advantage System$170
- INTERSTIM ICON$160
- REVI$150
- Lynx System$148
- Porges Coloplast$137
- Bard Urinary Drainage Bag$124
- Cysview$120
- Vivally$101
- ALTIS$101
How this compares
$346,006 in reported general payments places this provider in the 95th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 66 | $48,140 |
| MyrbetriqMirabegron | 54 | $38,999 |
| Mirabegron ErMirabegron | 15 | $13,907 |
| Estradiol | 44 | $7,266 |
| Methenamine Hippurate | 57 | $7,076 |
| YuvafemEstradiol | 32 | $4,306 |
| Tamsulosin Hcl | 74 | $1,401 |
| Tadalafil | 15 | $1,204 |
| Potassium Citrate ErPotassium Citrate | 15 | $930 |
| Oxybutynin Chloride ErOxybutynin Chloride | 44 | $628 |
| NitrofurantoinNitrofurantoin Macrocrystal | 14 | $380 |
| Finasteride | 17 | $207 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $158 | $48,14066 claims |
| Astellas Pharma US IncMyrbetriq | $355 | $38,99954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
Other urogynecology and reconstructive pelvic surgery in Stony Brook
- Justina TamStony Brook$12K
- Andre PlairStony Brook$5K
- Dara ShalomGreat Neck$94K
- Harvey WinklerGreat Neck$81K
- Robert MoldwinNew Hyde Park$35K
- Nitya AbrahamBronx$24K
- Cornelius VerhoestPoughkeepsie$21K
- Abeer EddibCheektowaga$19K
- Wai LeeNew Hyde Park$17K
- Doreen ChungNew Hyde Park$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.